literature

HBV mutation literature information.

Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.

PMID: 22358132 2012 Antiviral therapy

Abstract: In the LAM+ADV group, patients with single rtN236T resistant mutation had higher rates of undetectable HBV DNA than those with the double mutant rtA181T/V+rtN236T at months 3-18 of therapy.

Abstract: LAM+ADV were less effective in patients with the double mutant rtA181T/V+rtN236T than the single rtN236T mutation.

Abstract: No virological breakthrough occurred except for one patient with rtN236T resistant mutation who experienced virological and biochemical breakthrough a

[Clinical application of DNA sequencing for detecting point mutations in hepatitis B virus associated with drug resistance].

PMID: 22381777 2012 Nan fang yi ke da xue xue bao

Abstract: RESULTS: Forty out of the 120 patients were found to have one or two point mutations associated with drug resistance, including 17 with L180M and M204V/I mutations (42.5%), 10 with M204V/I mutation (25%), 8 with N236T mutation (20%), 3 with L180M mutation (7.5%), and 1 with both A181V/T and N236T mutations (2.5%), and 1 with A181V/T mutation(2.5%).

Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing.

PMID: 22523569 2012 PloS one

Result: Other mutations resistant to adefovir were detected in 7 (50.0%) and 3 (21.4%) cases at A181TV and N236T, respectively (Table 4).

Table: N236T

Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.

PMID: 22585719 2012 Journal of medical virology

Abstract: Multiple logistic regression analysis showed that the rtN236T and time resistant strains occurred during ADV-treatment were statistically significant for influencing rtA181 variation types (P = 0.007 and P = 0.024, respectively), and the occurrence of rtA181T was found to be significantly earlier than rtA181V.

Abstract: Seventy-six patients (47.2%) were found to carry the rtA181V/T/S or rtN236T residue substitution, and most of them had viral rebound.

Abstract: The rtA181T occurs more frequently in patient

Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.

PMID: 22666402 2012 PloS one

Method: NA-resistance-related aa substitutions outside the B and C domains, such as rtI233V, rtN236T and rtM250I/V, were not considered relevant for the aims of the study, since they had not been detected du

Discussion: In addition, due to the 250-bp-length limitation of the standard GS-FLX chemistry, the relevant NA-resistant substitutions, rtI233V and rtN236T linked to ADV treatment failure, and rtM250I/V linked to ETV failure, located outside the B and C HBV RT functional domains, were excluded from the fragment analyzed.

In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.

PMID: 22668794 2012 Antiviral therapy

Abstract: To determine the antiviral activity of GLS4 against adefovir dipivoxil (ADV)-resistant HBV mutants, HepG2 cells transiently transfected with PUC-HBV1.2 plasmids that contained one of three major ADV-resistant mutations (rtA181T, rtA181V and rtN236T) were treated with GLS4.

Hepatitis B virus gene mutations in liver diseases: a report from New Delhi.

PMID: 22720023 2012 PloS one

Discussion: Drug resistant mutations to ADV have been reported mainly in the HBV polymerase domain D rtN236T or the domain B rtA181V/T, whereas a domain D rtN236T mutation does not overlap with the envelope gene, a mutation at rtA181T can result in a stop mutation in the envelope region of the S gene (SW172stop).

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.

PMID: 22728692 2012 Antiviral therapy

Abstract: After 12-month treatment, 8.1% (3/37) of patients in group A and 5.7% (2/35) of patients in group B had VR; among patients in group A, two had rtM204V/I and rtL180M and one had rtN236T, whereas the two patients in group B had rtM204I+rtL180M.

Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.

PMID: 22825811 2012 Journal of medical virology

Abstract: No known mutations, such as rtA181T/V associated with rtN236T or A194T that are associated with reduced susceptibility or resistance to tenofovir were detected.

Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.

PMID: 22882650 2012 Liver international

Abstract: RESULTS: Among 467 consecutive eligible patients (262 chronic hepatitis B patients, 105 cirrhotic patients and 100 hepatocellular carcinoma patients), the nucleos(t)ide analogues-related mutations (rtI169T, rtV173L, rtL180M, rtA181T, rtS202C, rtM204I/V, rtN236T) were found.

Method: The primary drug resistant mutations were defin

Browser Board

Co-occurred Entities

Filtrator